These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33771759)

  • 21. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.
    Raaschou P; Simard JF; Asker Hagelberg C; Askling J;
    BMJ; 2016 Jan; 352():i262. PubMed ID: 26823527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
    Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
    JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term treatment in rheumatoid arthritis: do biological and targeted-synthetic DMARDs increase the risk of malignancy?
    Fagni F; Simon D
    Rheumatology (Oxford); 2022 May; 61(5):1758-1759. PubMed ID: 34648000
    [No Abstract]   [Full Text] [Related]  

  • 24. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
    Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
    Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.
    Montastruc F; Renoux C; Dell'Aniello S; Simon TA; Azoulay L; Hudson M; Suissa S
    Rheumatology (Oxford); 2019 Apr; 58(4):683-691. PubMed ID: 30535094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs.
    Sood A; Raji MA
    Clin Rheumatol; 2021 Apr; 40(4):1221-1231. PubMed ID: 32862311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis.
    Park SK; Lee MY; Jang EJ; Kim HL; Ha DM; Lee EK
    Clin Exp Rheumatol; 2017; 35(4):689-699. PubMed ID: 28079510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis.
    Choy EH
    Rheumatology (Oxford); 2019 Nov; 58(Suppl 5):v51-v55. PubMed ID: 31682274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
    Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
    Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
    Nakayamada S; Kubo S; Iwata S; Tanaka Y
    BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
    Borren NZ; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis.
    Baganz L; Listing J; Kekow J; Eisterhues C; Wassenberg S; Zink A; Strangfeld A
    Semin Arthritis Rheum; 2020 Feb; 50(1):36-41. PubMed ID: 31350056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
    Tarp S; Eric Furst D; Boers M; Luta G; Bliddal H; Tarp U; Heller Asmussen K; Brock B; Dossing A; Schjødt Jørgensen T; Thirstrup S; Christensen R
    Rheumatology (Oxford); 2017 Mar; 56(3):417-425. PubMed ID: 28013201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.
    Solomon DH; Kremer JM; Fisher M; Curtis JR; Furer V; Harrold LR; Hochberg MC; Reed G; Tsao P; Greenberg JD
    Semin Arthritis Rheum; 2014 Feb; 43(4):489-97. PubMed ID: 24012043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials.
    Liu Y; Fan W; Chen H; Yu MX
    Asian Pac J Cancer Prev; 2014; 15(8):3403-10. PubMed ID: 24870729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
    Varisco PA; So A
    Rev Med Suisse; 2014 Jan; 10(414):187-91. PubMed ID: 24624736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignancy and Janus Kinase Inhibition.
    Sivaraman P; Cohen SB
    Rheum Dis Clin North Am; 2017 Feb; 43(1):79-93. PubMed ID: 27890175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.